Copyright
©The Author(s) 2016.
World J Gastroenterol. Feb 14, 2016; 22(6): 2104-2110
Published online Feb 14, 2016. doi: 10.3748/wjg.v22.i6.2104
Published online Feb 14, 2016. doi: 10.3748/wjg.v22.i6.2104
Table 1 Patient characteristics n (%)
| Prospective group (n = 57) | Retrospective group (n = 613) | P value | |
| Age (yr) | 52.4 (17-94) | 58.9 (5-96) | 0.062 |
| Gender (M:F) | 35 (61):22 (39) | 320 (52):293 (48) | 0.179 |
| Comorbidity | |||
| None | 14 (25) | 219 (36) | |
| Heart disease | 13 (23) | 127 (21) | |
| Hypertension | 19 (33) | 170 (28) | |
| Pulmonary disease | 5 (9) | 69 (11) | |
| Diabetes mellitus | 4 (7) | 57 (9) | |
| Previous pancreatitis | 15 (26) | 38 (6) | < 0.001 |
| Duration of pain (h) | 24 (0-504) | 20 (0-0.592) | |
| Severe pancreatitis | |||
| CRP | 31 (54) | 276 (45) | 0.975 |
| CT | 3 (10) | 33 (10) | 0.945 |
| Complications | 0.660 | ||
| None | 45 (79) | 497 (81) | |
| Systemic | 8 (14) | 89 (14.9) | |
| Local | 4 (7) | 43 (7.2) | |
| Mortality | 1 (2) | 36 (6) | 0.356 |
| Severity of pancreatitis | 0.713 | ||
| Mild | 50 (88) | 521 (85) | |
| Moderate severe | 2 (4) | 54 (9) | |
| Severe | 5 (8) | 38 (6) |
Table 2 Investigations during hospital stay and/or follow-up, n (%)
| Prospective group (n = 57) | Retrospective group (n = 585 evaluable) | P value | |
| All patients with ultrasonography | 51 (89.5) | 420 (71.8) | 0.007 |
| All patients with CT | 45 (78.9) | 311 (53.1) | |
| All patients with MRI | 32 (56.1) | 196 (33.5) | 0.001 |
| US | 5 (8.8) | 142 (24.3) | |
| US + CT | 16 (28.1) | 143 (24.4) | |
| US + MRI | 7 (12.3) | 86 (14.7) | |
| US + CT+ MRI | 23 (40.3) | 49 (8.4) | |
| CT alone | 4 (7.0) | 88 (15.4) | |
| CT + MRI | 2 (3.5) | 31 (5.3) | |
| MRI alone | 0 | 30 (5.1) | |
| No imaging | 0 | 16 (2.7) |
Table 3 Cause of acute pancreatitis in the prospective and retrospective group n (%)
| Prospective group (n = 57) | Retrospective group (n = 613) | P value | |||
| Patients | Patients using medicines1 | Patients | Patients using medicines1 | ||
| Bile stone | 23 (40.4) | 13 (57) | 271 (44.2) | 4 (0.1) | < 0.001 |
| Bile stone or alcohol | 4 (7.0) | 4 (100) | 14 (2.3) | ||
| Alcohol | 6 (10.5) | 1 (17) | 87 (14.2) | 1 (0.1) | |
| Hypertriglyceridemia | 3 (5.2) | 3 (100) | 8 (1.3) | ||
| ERCP | 1 (1.8) | 0 | 19 (3.1) | ||
| PTC | 1 (1.8) | 0 | 0 | ||
| Tumor/cancer pancreas | 1 (1.8) | 0 | 9 (1.5) | ||
| Pancreas divisum | 2 (3.5) | 1 (50) | 1 (0.2) | ||
| Stone in pancreatic duct | 1 (1.8) | 0 | 1 (0.2) | ||
| Postoperative pancreatitis | 0 | 0 | 3 (0.5) | ||
| Trauma | 0 | 0 | 1 (0.2) | ||
| Viral infection | 0 | 0 | 2 (0.3) | ||
| Medicines1 | 11 (19.3) | 11 (100) | 15 (2.4) | 15 (100) | |
| Unknown2 | 4 (7.0) | 0 | 182 (29.7) | 0 | |
| All | 57 (100) | 33 (58) | 613 (100) | ||
Table 4 Details of drugs used in patients with possible etiologies in the prospective group
| Etiology | Generic name | n |
| Bile stone (n = 23) | Azathioprine | 1 |
| of which medicine users (n = 13) | Simvastatin | 1 |
| Diclofenac | 1 | |
| Amipril | 1 | |
| Enalapril | 1 | |
| Drospirenin/etinylostradiol | 1 | |
| Simvastatin, Amipril | 1 | |
| Atorvastatin, Ezetimib | 1 | |
| Amipril | 1 | |
| Simvastatin, Amipril, Diclofenac | 1 | |
| Methotrexate | 1 | |
| Atorvastatin | 1 | |
| Simvastatin, | 1 | |
| Candesartan hydrochlorothiazide | 1 | |
| Simvastatin, | 1 | |
| Losartan hydrochlorothiazide | ||
| Bile stone or alcohol (n = 4) | Estradiol | 1 |
| of which medicine users (n = 4) | Ramipril, Prednisolone | 1 |
| Estradiol | 1 | |
| Diclofenac | 1 | |
| Alcohol (n = 6) | Prednisolone | 1 |
| of which medicine users (n = 1) | ||
| Hypertriglyceridemia (n = 3) | Gabapentin | 1 |
| of which medicine users (n = 3) | Simvastatin | 1 |
| Venlafaxine | 1 | |
| Medication (n = 11) | Azathioprine | 2 |
| of which medicine users (n = 11) | Simvastatin | 1 |
| Atorvastatin | 1 | |
| Venlafaxine, Ramipril, Asparginase | 1 | |
| Atorvastatin | 1 | |
| Methotrexate, Prednisolone, Etanercept | 1 | |
| Mycofenolic acid, Tacrolimus, Prednisolone | 1 | |
| Cyclosporine, Pravastatin, Simvastatin, Ramipril | 1 | |
| Diclofenac | 1 | |
| Simvastatin, Losartan hydrochlorothiazide | 1 | |
| Pancreas divisum (n = 2) | Simvastatin | 1 |
| of which medicine users (n = 1) | ||
| Total number | 34 |
Table 5 Number of drugs used in patients with medicines as a possible etiology
| Use of a single drug | Use of two drugs | Use of three drugs | |||
| Name | n | Name | n | Name | n |
| Azathioprine | 3 | Simvastatin, Amlodipine | 1 | Simvastatin, Ramipril. | 2 |
| Simvastatin | 4 | Simvastatin, Candesartan hydrochlorothiazide | 1 | Diclofenac | |
| Gabapentin | 1 | Simvastatin, Losartan hydrochlorothiazide | 2 | Atorvastatin, Ezetimib, Ramipril | 1 |
| Methotrexate | 1 | Simvastatin, Pravastatin | 1 | ||
| Estradiol | 1 | Ramipril, Prednisolone | 1 | Atorvastatin, Venlafaxine, Ramipril | 1 |
| Asparginase | 1 | Methotrexate, Etanercept, Prednisolone | 1 | ||
| Diclofenac | 2 | Mycofenolic acid, Tacrolimus, Prednisolone | 1 | ||
| Atorvastatin | 2 | ||||
| Venlafaxine | 1 | ||||
| Furosemide | 1 | ||||
| Enalapril | 1 | ||||
| Drospirenin etinylostradiol | 1 | ||||
| Estradiol | 1 | ||||
| Prednisolone | 1 | ||||
| Sum | 21 | 6 | 6 | ||
- Citation: Rashidi M, Røkke O. Prospective evaluation of the cause of acute pancreatitis, with special attention to medicines. World J Gastroenterol 2016; 22(6): 2104-2110
- URL: https://www.wjgnet.com/1007-9327/full/v22/i6/2104.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i6.2104
